Sonoma pharmaceuticals reports second fiscal quarter 2024 financial results

Gross profit percentage of 36% for the quarter, up 1% from first fiscal quarter 2024 total operating expenses decreased for the quarter and six months ended september 30, 2023 compared to same period prior year european revenues increased 3% for the quarter and 13% for the six months ended september 30, 2023, compared to the same periods prior year boulder, co / accesswire / november 13, 2023 / sonoma pharmaceuticals, inc. (nasdaq:snoa), a global healthcare leader developing and producing stabilized hypochlorous acid (hocl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced financial results for its second fiscal quarter ended september 30, 2023. "in the second quarter of our fiscal year 2024, we continued to reduce costs while maintaining our diligent efforts to expand sales and increase our presence in u.s. and international markets," said amy trombly, ceo of sonoma.
SNOA Ratings Summary
SNOA Quant Ranking